Nektar Therapeutics (NKTR)
$0.7885
Rating:
Recommendation:
Strong Buy
| Symbol | NKTR |
|---|---|
| Price | $0.7885 |
| Beta | 1.102 |
| Volume Avg. | 2.37M |
| Market Cap | 149.212M |
| Shares () | - |
| 52 Week Range | 0.78-6.37 |
| 1y Target Est | - |
| DCF Unlevered | NKTR DCF -> | |
|---|---|---|
| DCF Levered | NKTR LDCF -> | |
| ROE | -79.81% | Strong Sell |
| ROA | -51.82% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 93.82% | Buy |
| P/E | -0.45 | Neutral |
| P/B | 0.40 | Neutral |
Latest NKTR news
About
Download (Excel)Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.